JP2015180198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015180198A5 JP2015180198A5 JP2015044097A JP2015044097A JP2015180198A5 JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5 JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5
- Authority
- JP
- Japan
- Prior art keywords
- serine
- serine racemase
- barrier function
- expression level
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010006152 Serine racemase Proteins 0.000 claims 15
- 102100035717 Serine racemase Human genes 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 9
- 238000012216 screening Methods 0.000 claims 9
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 6
- 229930195711 D-Serine Natural products 0.000 claims 6
- 230000008591 skin barrier function Effects 0.000 claims 6
- 210000002510 keratinocyte Anatomy 0.000 claims 5
- 210000003491 skin Anatomy 0.000 claims 5
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 241000283074 Equus asinus Species 0.000 claims 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- 229960001327 pyridoxal phosphate Drugs 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- -1 vitamin B 6 compound Chemical class 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015044097A JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
| JP2019186327A JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014043073 | 2014-03-05 | ||
| JP2014043073 | 2014-03-05 | ||
| JP2015044097A JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Division JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015180198A JP2015180198A (ja) | 2015-10-15 |
| JP2015180198A5 true JP2015180198A5 (enExample) | 2016-04-28 |
| JP6854073B2 JP6854073B2 (ja) | 2021-04-07 |
Family
ID=54328827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015044097A Active JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
| JP2019186327A Active JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Active JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6854073B2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7172984B2 (ja) * | 2017-03-24 | 2022-11-16 | 味の素株式会社 | 角層機能改善剤 |
| JP7366428B2 (ja) * | 2018-08-27 | 2023-10-23 | Kagami株式会社 | 乾癬を判定するための皮膚試料の分析方法及びシステム |
| JP7237689B2 (ja) * | 2019-03-28 | 2023-03-13 | 株式会社ナリス化粧品 | ストレスに起因する皮膚バリア機能改善剤のスクリーニング方法 |
| JP2023056255A (ja) * | 2021-10-07 | 2023-04-19 | エスエス製薬株式会社 | 色素斑形成抑制剤、メラノソーム貪食亢進抑制剤及び表皮分化能改善剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4202638B2 (ja) * | 2001-12-12 | 2008-12-24 | 丸善製薬株式会社 | コラーゲン産生促進剤、エラスターゼ阻害剤、コラゲナーゼ阻害剤及び老化防止用皮膚化粧料 |
| JP2005041861A (ja) * | 2003-07-09 | 2005-02-17 | Takeda Chem Ind Ltd | 皮膚角層水分量低下抑制剤 |
| JP5795960B2 (ja) * | 2009-09-14 | 2015-10-14 | 株式会社 資生堂 | 紫外線障害軽減組成物 |
-
2015
- 2015-03-05 JP JP2015044097A patent/JP6854073B2/ja active Active
-
2019
- 2019-10-09 JP JP2019186327A patent/JP6934925B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McGaw et al. | Cytotoxicity of African medicinal plants against normal animal and human cells | |
| Tsang et al. | Purpurin suppresses Candida albicans biofilm formation and hyphal development | |
| Cappellari et al. | “The Social Network” and muscular dystrophies: the lesson learnt about the niche environment as a target for therapeutic strategies | |
| JP2015180198A5 (enExample) | ||
| BR112017010190A2 (pt) | sistema para medição de características, método de medição | |
| MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
| WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
| ES2571111T3 (es) | Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia | |
| Liu et al. | Visualization of positive and negative sense viral RNA for probing the mechanism of direct-acting antivirals against hepatitis C virus | |
| RU2017122187A (ru) | Клеточный способ определения эффективности дефибротида | |
| MY196578A (en) | Method for Determining Stage of Periodontal Disease | |
| AU2018275891A1 (en) | Articles of manufacture and methods related to toxicity associated with cell therapy | |
| EP4549574A3 (en) | Anti-tmem-180 antibody, anticancer drug and cancer testing method | |
| WO2012109258A3 (en) | Compositions adn methods for monitoring oxalate | |
| CR20210551A (es) | Método de monitoreo de las concentraciones de perácidos mediante medidas de conductividad y composición de perácidos | |
| RU2012153849A (ru) | Способ оценки токсичности продукции из полимерных и текстильных материалов | |
| JP2014208601A5 (enExample) | ||
| Hagihara et al. | An experimental study about survey response rate Basic study of efficient strategies to raise the participation rate of Mobility Management | |
| Pakotiprapha et al. | Bridging the Gap: Can COVID-19 Research Help Combat African Swine Fever? | |
| WO2016178083A3 (en) | Method for measuring tear constitutents in a tear sample | |
| DE602005008710D1 (de) | Verfahren zur untersuchung der aktivität von ionenkanälen | |
| PL410454A1 (pl) | Sposób identyfikowania odpowiedzi chorego na łuszczycę na leczenie genisteiną molekularny test oraz zastosowanie ekspresji genów do wykrywania in vitro łuszczycy | |
| JP2016088926A5 (enExample) | ||
| RU2017139718A (ru) | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток | |
| JP2014028787A5 (enExample) |